Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06646276 | A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | PHASE3 | RECRUITING | 530 | — | — | Feb 25, 2025 | Sep 5, 2031 | Jun 1, 2026 | 183 | United States, Argentina +24 |
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Arm B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-986489 (BMS-986012+Nivolumab) | BIOLOGICAL | Specified dose on specified days |
| Atezolizumab | BIOLOGICAL | Specified dose on specified days |
| Carboplatin | DRUG | Specified dose on specified days |
| Etoposide | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). * Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale. * Participants must have at least one tumor that can be measured...